0M0E Stock Chart & Stats
€3.43
€0.00(0.00%)
At close: 4:00 PM EST
€3.43
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.24 - €3.49
Previous CloseN/A
Volume0.00
Average Volume (3M)2.19K
Market Cap
€318.20M
Enterprise Value€473.37
Total Cash (Recent Filing)€70.55M
Total Debt (Recent Filing)€226.18M
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding91,436,195
10 Day Avg. Volume4,055
30 Day Avg. Volume2,190
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.09
Price to Sales (P/S)0.50
P/FCF Ratio15.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.33
Revenue Forecast (FY)€662.80M
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistent positive operating and free cash flow in 2025 shows the business can convert sales into cash, providing liquidity to fund working capital, service debt and support capex. That cash-generation ability cushions the company through cycles and underpins operational resilience.
Business Model ResilienceA manufacturing-based model selling basic chemicals to industrial customers creates durable demand links to industrial activity. Revenue drivers like tonnage, plant utilization and pass-through of raw-material and energy costs give management levers to protect margins and absorb cyclical swings.
Moderate Leverage LevelAlthough leverage has risen, debt remaining below equity in 2025 means the balance sheet retains a capital cushion. This structural buffer improves solvency risk profile relative to highly leveraged peers and supports access to financing and strategic flexibility in the medium term.
Bears Say
Profitability DeteriorationA shift from multi-year profits to widening losses indicates sustained margin compression and operational stress. Persisting losses reduce retained earnings, limit reinvestment capacity, and increase vulnerability to further demand shocks or cost inflation over the coming months.
Revenue Decline TrendFalling revenue over several years suggests weakening demand or pricing power in core markets. Lower top-line volumes reduce fixed-cost absorption, exacerbate margin pressure, and could force capacity adjustments or margin-dilutive discounting if the trend persists.
Rising Leverage & Declining EquityAn increasing debt-to-equity trend and declining equity weaken the company’s financial flexibility. Higher leverage raises refinancing and interest-rate risk, constrains strategic investments, and heightens the impact of any further earnings deterioration on solvency.
Ercros SA News
0M0E FAQ
What was Ercros SA’s price range in the past 12 months?
Ercros SA lowest share price was €2.24 and its highest was €3.49 in the past 12 months.
What is Ercros SA’s market cap?
Ercros SA’s market cap is €318.20M.
When is Ercros SA’s upcoming earnings report date?
Ercros SA’s upcoming earnings report date is Nov 11, 2026 which is in 98 days.
How were Ercros SA’s earnings last quarter?
Ercros SA released its earnings results on Jul 28, 2026. The company reported -€0.043 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Ercros SA overvalued?
According to Wall Street analysts Ercros SA’s price is currently Overvalued.
Does Ercros SA pay dividends?
Ercros SA does not currently pay dividends.
What is Ercros SA’s EPS estimate?
Ercros SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ercros SA have?
Ercros SA has 91,436,195 shares outstanding.
What happened to Ercros SA’s price movement after its last earnings report?
Ercros SA reported an EPS of -€0.043 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.144%.
Which hedge fund is a major shareholder of Ercros SA?
Currently, no hedge funds are holding shares in GB:0M0E
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ercros SA
Ercros, S.A. is a Spanish industrial group primarily engaged in the production and distribution of basic chemicals, intermediate chemical products, and pharmaceuticals. The company also extends its market reach through export activities. Its diverse operations are structured into three main divisions: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment manufactures a broad spectrum of products, including ammonia, bioplastics, various caustic solutions (potash and soda), chlorine, chloroisocyanurates, dicalcium phosphate, dichloroethane, hydrochloric acid, hydrogen peroxide, potassium carbonate, PVC compounds, sodium chlorate and chlorite, sodium hypochlorite, and vinyl chloride monomers. These compounds serve as vital industrial intermediates, essential for applications such as purifying drinking and wastewater, maintaining swimming pools, bleaching paper and textiles, and formulating detergents, solvents, and strippers. They also find use in producing printing inks, animal feed, and cooling equipment. The Intermediate Chemicals division supplies products like formaldehyde, various glues and resins, molding powders, paraformaldehyde, pentaerythritol and dipentaerythritol, and sodium formate. These are crucial for manufacturing wood-based panels like chipboards, decorative laminates, and plywoods, as well as resins, paints, and varnishes for the furniture and decoration sectors. Furthermore, they are integral to producing electrical components such as plugs and switches, and contribute to household, sanitary, and packaging materials within the textile tanning industry. Ercros's Pharmacy segment focuses on developing and producing active pharmaceutical ingredients (APIs) and intermediate compounds. Its portfolio includes agents for various therapeutic areas, such as bacterial infections (e.g., azithromycin, clarithromycin, erythromycins, calcium and sodium fosfomycin, fosfomycin trometamol, fusidic acid), high cholesterol (amlodipine besylate), ulcers (famotidine), and fungal infections. With a rich history, Ercros, S.A. was established in 1817 and maintains its corporate headquarters in Barcelona, Spain.
Technical Analysis
Faes Farma
―
Grifols
―
LABORATORIO REIG JOFRE
―
Laboratorios Farmaceuticos Rovi
―
Repsol
―





